# Molecular mechanisms of prostate cancer metastasis

> **NIH NIH R01** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2022 · $464,375

## Abstract

Although locally invasive prostate cancer is nearly always curable, metastatic prostate cancer is usually fatal.
Our research is focused on elucidating mechanisms that promote metastatic progression and underlie
phenotypic heterogeneity of metastases. Toward this end, we have developed a series of genetically engineered
mouse models (GEMMs) that recapitulate the phenotypic heterogeneity of metastatic prostate cancer. The
centerpiece of this collection of GEMMs is the NPKEYFP mouse model, which develops highly penetrant bone
metastasis. This model is complemented by additional GEMMs, namely the NPMEYFP and NPp53EYFP mice, that
display distinctive metastatic phenotypes. We have performed transcriptomic analyses at the bulk tissue and
single-cell level of prostate tumors and metastases from these GEMMs to identify candidate drivers (master
regulators (MRs)) of metastatic progression and phenotypic heterogeneity. Furthermore, we have isolated
circulating tumor cells (CTCs) from these metastatic GEMMs to study their heterogeneity at the cellular level. In
particular, we have established a pipeline to isolate and molecularly characterize individual CTCs as organoids
and to study the CTCs at the single-cell level. Our investigations have uncovered several themes that shape the
direction of our research. In particular, our findings support the concept that specific mutational events (such as
loss of function of p53 and activation of MYC and RAS signaling) as well as cellular plasticity are key drivers of
metastatic progression and phenotypic heterogeneity.
Thus, we will investigate our hypothesis that heterogeneity of metastasis represents the culmination of
molecular, cellular, and organismal differences, as follows: In Aim 1, we will study mechanisms of metastatic
progression by: (a) investigating the role of the histone methyltransferase NSD2 by analyses of a new GEMM
with gain of function of NSD2 in prostate tumors; and (b) studying cell-intrinsic mechanisms of metastatic
progression at the single-cell level in primary tumors and lung and bone metastases. In Aim 2, we will investigate
molecular mechanisms of phenotypic heterogeneity of metastasis by analyses of our GEMMs that display a
range of metastatic phenotypes. In Aim 3, we will examine cellular heterogeneity of circulating tumor cells (CTCs)
at the single-cell level using organoid models and single-cell sequencing approaches. Taken together, our
studies are highly innovative in their combination of sophisticated inducible mouse models, single-cell analyses,
organoid culture methods, and computational systems approaches to investigate a central problem in cancer
biology. Our studies of precision modeling of prostate cancer metastasis may ultimately help guide individualized
patient care.

## Key facts

- **NIH application ID:** 10453610
- **Project number:** 5R01CA183929-07
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** Cory Abate-Shen
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $464,375
- **Award type:** 5
- **Project period:** 2015-01-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10453610

## Citation

> US National Institutes of Health, RePORTER application 10453610, Molecular mechanisms of prostate cancer metastasis (5R01CA183929-07). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10453610. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*